The OvaCure Team
Scientific & Clinical Advisory Board
The members of the OvaCure Scientific and Clinical Advisory Board are carefully selected according to their international experience and recognition in the following therapeutic areas: gynaecology, oncology, immunotherapy and T-cell therapy. This equips OvaCure with the required competences to treat and cure ovarian cancer. The members of the Scientific and Clinical Advisory Board do not receive compensation, but have the opportunity to submit projects to the Project Call.
MD, Professor, Leader of Tumor biology at Ludwig Centre of the University of Lausanne, CH
George Coukos is a professor at the University of Lausanne and Chief Director of the Oncology Department at the Centre Hospitalier Universitaire Vaudois (CHUV). He is the Director of Ludwig Cancer Research Lausanne which focuses on tumor immunology and immunotherapy. Professor Coukos has established and currently directs the Swiss Cancer Center in Lausanne for translational and clinical cancer research. Furthermore, he is a tenured Professor at the University of Pennsylvania School of Medicine where he established and directed the Ovarian Cancer Research Center.
MD, Professor, Perelman School of Medicine, University of Pennsylvania, USA
Carl June is a professor at the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. He is an expert in Adoptive T-cell therapy and T-cell co-stimulation. Professor June also stands as Director of the Center for Cellular Immunotherapy at the University of Pennsylvania.
PhD, Managing Director of the Anticancer Fund and Co-founder of OvaCure, BE
Lydie Meheus, PhD, is Managing Director of the Anticancer Fund (ACF) and Executive Director of Reliable Cancer Therapies (RCT). She holds a PhD in Protein Biochemistry. In 1987, Meheus began work as a senior researcher at Innogenetics, Belgium, where she subsequently held numerous positions. When Innogenetics incorporated its therapeutic activities into a new company, GENimmune, in 2007, she became Vice President for R&D. She began working at RCT in 2009 and ACF in 2013.
Mansoor Raza Mirza
MD, Chief Oncologist, Rigshospitalet, Chairman, Danish Gynecologic Cancer Society, DK
Mansoor Raza Mirza is Chief Oncologist at the Department of Oncology, University Hospital of Copenhagen, Denmark. He has broad experience in clinical protocol development, trial conduct and clinical trial regulations. He represents Nordic Society of Gynecological Oncology in the European Network of Gynecologic Oncology Trials and in the Gynecologic Cancer Intergroup. Professor Mirza is the Chairman of the Danish Gynecological Cancer Society.
MD, PhD, Professor of Medical Oncology at the University Paris Descartes, FR
Eric Pujade-Lauraine is Founder of the French GINECO Group, devoted to clinical research in gynecologic cancer. Professor Pujade-Lauraine is Head of the Women Cancer and Clinical research Department at Hôpitaux Universitaires Paris Centre, site Hôtel-Dieu, AP-HP in Paris, France and Co-chair of the French gynecologic rare tumor network (TMRG). He is a member of the American Society of Clinical Oncology (ASCO), the
European Society for Medical Oncology (ESMO), the Executive Board of the European Network of Gynecological Trials (ENGOT). Professor Pujade-Lauraine is past Chair of the Gynecologic Cancer Academy (GCA), the ENGOT Translational group and the international Gynecologic Cancer Intergroup (GCIG).
Inge Marie Svane
MD, DMSc, Professor, Copenhagen University Hospital Herlev, Center for Cancer Immune Therapy (CCIT), DK
Inge Marie Svane is Head of Oncologic treatment of disseminated melanoma in Eastern Denmark, She is also a member of the Danish Melanoma Grou and conducts research on TILs which have produced encouraging results in malignant melanoma. Currently a phase III trial in malignant melanoma has been initiated.